Clinical Trials Logo

Clinical Trial Summary

This will be the first-in-human (FIH) study with CXA-10. The main purpose of this trial is to demonstrate the tolerability, safety and pharmacokinetics (PK) of CXA-10 at various incremental doses, and to demonstrate the safety and tolerability of the rate of the emulsion vehicle infusion in healthy volunteers. In addition, associated pharmacodynamic (PD) effects of CXA-10 will be investigated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02127190
Study type Interventional
Source Complexa, Inc.
Contact
Status Completed
Phase Phase 1
Start date April 2014
Completion date December 2014

See also
  Status Clinical Trial Phase
Completed NCT02248051 - Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury Phase 1
Completed NCT03244514 - Biomarker-guided Implementation of the AKI Bundle N/A
Withdrawn NCT04598516 - Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
Recruiting NCT05275218 - Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery N/A
Recruiting NCT06259760 - AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia
Recruiting NCT06295393 - Renin Angiotensin Aldosterone System In Septic Kids
Completed NCT03453996 - Contrast RISK (Reducing Injury Sustained by Kidneys) N/A
Recruiting NCT02095275 - Exploring the Relationship Among BNP, Fluid Status and Acute Kidney Injury in Critically Ill Patients N/A
Not yet recruiting NCT03369561 - Comparison Between Right and Left Ventricular Systolic Dysfunction as a Risk Factors for Aki in Critical Care Patients N/A
Completed NCT05612802 - A New Marker for Early Diagnosis of Pneumoperitoneum-Related Acute Kidney Injury: Insulin-Like Growth Factor-1 (IGF-1) N/A
Not yet recruiting NCT03830450 - Biomarkers of Acute Kidney Injury in Cardiac Surgery
Completed NCT04592406 - Data on the Prevention of Complications of Prophylactic Intravenous Hydration in Patients With eGFR < 30